GO
Loading...

Enter multiple symbols separated by commas

Teva Pharmaceutical Industries Ltd

More

  • April 21- Perrigo Company PLC is set to reject a $29 billion unsolicited takeover offer from generics drugmaker Mylan NV as soon as this week, according to a source familiar with the matter. Teva said that its offer for Mylan is contingent on the company not completing an acquisition of Perrigo or any alternative transaction. Representatives from Perrigo and...

  • TEL AVIV/ NEW YORK, April 21- Generic drugmaker Teva Pharmaceutical Industries Ltd. on Tuesday proposed buying smaller rival Mylan for $40 billion, saying it was a better deal than Mylan's alternate offer to buy Perrigo Co. Teva said the stock-and-cash offer of $82 a share represented a 48 percent premium to Mylan's stock price on March 10, which it said was the...

  • UPDATE 1-Teva makes $82 per share offer for Mylan Tuesday, 21 Apr 2015 | 8:57 AM ET

    TEL AVIV/ NEW YORK, April 21- Generic drugmaker Teva Pharmaceutical Industries Ltd. said on Tuesday that it had proposed buying rival Mylan for $82.00 per share in a mix of stock and cash.

  • Teva makes $40B bid for Mylan Tuesday, 21 Apr 2015 | 8:49 AM ET
    An employee collects newly-manufactured pills at Teva Pharmaceutical Industries headquarters in Jerusalem, Israel.

    Teva said the stock-and-cash offer of $82 a share represented a 48 percent premium to Mylan's stock price on March 10.

  • Teva considering bid for Mylan: Report Friday, 17 Apr 2015 | 2:31 PM ET
    An employee collects newly-manufactured pills from a machine at the tablet production plant at Teva Pharmaceutical Industries Ltd.'s headquarters in Jerusalem, Israel.

    Drugmaker Teva is considering making a bid for Mylan, but has not yet made a decision on an offer, Dow Jones reported.

  • Big pharma M&A may keep booming, CEOs say Thursday, 16 Apr 2015 | 3:44 PM ET
    Generic copies of Merck & Co.'s cholesterol pill Zocor and Pfizer Inc.'s Zoloft antidepressant.

    For Pfizer and Merck, two big names that have ridden the merger wave, buying up more business is a possibility, their CEOs said.

  • Former Teva CEO's new gig at Ovid Therapeutics Thursday, 16 Apr 2015 | 6:10 AM ET

    After an abrupt departure, Former Teva CEO Jeremy Levin is now leading a start-up focused on rare neurological disorders.

  • Cramer Remix: This stock may be ready to break out Thursday, 9 Apr 2015 | 7:04 PM ET
    Jim Cramer on the set of Mad Money

    “Mad Money” host Jim Cramer turns your attention to a social star that may be ready to roar.

  • Mylan seeks to buy Perrigo for $205 per share Wednesday, 8 Apr 2015 | 11:40 AM ET
    Mylan headquarters in Canonsburg, Pa.

    Perrigo shares shot higher after news that Mylan proposed to buy Perrigo for $205 per share.

  • Early movers: MRH, JCI, DHI, PHG, TEVA, CVC & more Tuesday, 31 Mar 2015 | 7:51 AM ET
    A trader works on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • *China shares hit seven-year high on ambitious Silk Road project. Also Monday, Israel's Teva Pharmaceutical Industries said it would buy U.S. biopharmaceutical firm Auspex Pharmaceuticals Inc for $3.5 billion, and Ireland's Horizon Pharma Plc agreed to buy U.S. drugmaker Hyperion Therapeutics Inc for about $1.1 billion. Earlier, China unveiled details of an...

  • Stocks surge 1%; Dow up over 250 points Monday, 30 Mar 2015 | 4:00 PM ET
    A trader works on the floor of the New York Stock Exchange.

    U.S. stocks closed more than 1 percent higher on Monday amid encouraging talk of stimulus in Asia, as investors eyed the week's economic data.

  • Merger Monday is back: What to buy Monday, 30 Mar 2015 | 11:44 AM ET

    This year is on track to surpass the record set in 2014 for M&A. "Merger Monday" is back. Here's how to trade it.

  • US stocks look set for another rebound, data eyed Monday, 30 Mar 2015 | 8:30 AM ET
    Traders work on the floor of the New York Stock Exchange.

    U.S. stock index futures indicated a sharply higher open on Monday, following European stocks' move upwards, ahead a data-packed week.

  • Early movers: CTRX, ASPX, DD, ALTR, MSG & more Monday, 30 Mar 2015 | 7:58 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Teva to buy Auspex for $101/share in cash Monday, 30 Mar 2015 | 7:09 AM ET
    An employee collects newly-manufactured pills at Teva Pharmaceutical Industries headquarters in Jerusalem, Israel.

    Teva said the deal would add a portfolio of drugs for the treatment of central nervous system disorders.

  • Three trades to go before the closing bell Monday, 16 Mar 2015 | 1:58 PM ET

    The "Halftime Report" traders give their trades for the second half.

  • CVS: Copycat drugs may bring price cuts of 40-50% Thursday, 12 Mar 2015 | 7:14 AM ET

    Copycat biotech drugs in the U.S. market could cut prices of expensive medications by 40 percent to 50 percent, said a top CVS Health exec.

  • March 2- U.S. generic drug maker Mylan Inc is still on the prowl for more deals, after completing the multibillion-dollar acquisition of some of Abbott Laboratories' non-U.S. businesses just last week. The company forecast 2015 revenue of $9.6 billion to $10.1 billion and adjusted earnings of $4 to $4.30 per share. The company said it still expects to launch a...

  • *Q4 adjusted EPS $1.31, in line with expectations. TEL AVIV, Feb 5- Teva Pharmaceutical Industries is ready to return to making acquisitions, it said on Thursday, after a year of focusing on costs under its new chief executive. The company posted fourth-quarter earnings of $1.31 per diluted share, excluding one-time items, against $1.42 a year earlier.